Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR

Additional Metadata
Persistent URL	doi.org/10.1093/annonc/mdw375.01, hdl.handle.net/1765/126455
Journal	Annals of Oncology
Organisation	Department of Hematology
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Weisel, K., Palumbo, A., Chanan-Khan, A. A., Nooka, A., Spicka, I., Masszi, T., … Sonneveld, P. (2016). Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR. Annals of Oncology, 27. doi:10.1093/annonc/mdw375.01

Publication